With the release of ASCO abstracts, essentially a huge clinical trial data release ahead of the annual cancer conference, we witnessed a few pops and drops among biotech stocks. 

In this video, healthcare analyst David Williamson takes a closer look at two stocks seeing 20% moves -- Oncothyreon  and Halozyme -- and discusses what these events mean for investors.

Another topic health-care investors need to keep up on is Obamacare, as the law will undoubtedly have far-reaching effects. The Motley Fool's new free report, "Everything You Need to Know About Obamacare," lets you know how your health insurance, your taxes, and your portfolio will be affected. Click here to read more. 


The article Cancer Drug Drama Rocks 2 Biotech Stocks originally appeared on Fool.com.

David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Investing Like Warren Buffett

Learn from one of the world's best investors.

View Course »

What is Short Selling?

Make a profit when stocks prices fall.

View Course »